Manuel R. B.

Another major focus is non-small cell lung cancer, including EGFR-mutated, ALK-positive, KRAS G12C-mutant, and PD-L1-selected disease. The investigator is also involved in research across small cell lung cancer, resectable lung cancer, and thoracic tumors with central nervous system involvement.

• Advanced and metastatic non-small cell lung cancer
• Biomarker-driven lung cancer subtypes
• Resectable and locally advanced thoracic disease
• Small cell lung cancer and lung cancer with brain metastases

This area reflects a sustained interest in targeted and immuno-oncology strategies for lung and thoracic tumors.

The investigator is actively engaged in hematologic oncology, with studies spanning acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and aggressive B-cell lymphomas. The portfolio includes relapsed, refractory, and newly diagnosed blood cancers, alongside high-risk and molecularly defined subgroups.

• Acute leukemias and myelodysplastic syndromes
• Diffuse large B-cell lymphoma and mantle cell lymphoma
• Multiple myeloma and plasma cell disorders
• Chronic lymphocytic leukemia and related lymphoproliferative disease

Research in this domain also extends to cellular therapy, transplant-related settings, and novel immunotherapeutic approaches.

There is broad involvement in solid tumor research, especially renal cell carcinoma, urothelial carcinoma, prostate cancer, ovarian cancer, gastric cancer, and colorectal cancer. The research landscape also includes hepatocellular carcinoma, head and neck squamous cell carcinoma, and other advanced solid malignancies.

• Renal, urothelial, and prostate cancers
• Ovarian, gastric, and colorectal cancers
• Head and neck and hepatobiliary malignancies
• Advanced and biomarker-selected solid tumors

These activities align with interest in treatment options for difficult-to-manage metastatic and recurrent genitourinary and gastrointestinal cancers.

The investigator also contributes to studies in autoimmune disease, inflammatory bowel disease, systemic lupus erythematosus, psoriatic arthritis, and pulmonary sarcoidosis. Additional work spans cardiovascular disease, heart failure, atrial fibrillation, obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis.

• Autoimmune and rheumatologic disorders
• Inflammatory bowel and liver disease
• Cardiovascular and heart failure conditions
• Obesity, diabetes, and metabolic liver disease

This portfolio also includes neurologic and respiratory conditions such as migraine, Parkinson’s disease, and chronic obstructive pulmonary disease.